The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) guidelines all ...

When Jeanne Szurek, 69, was diagnosed with stage IV epidermal growth factor receptor (EGFR)-positive lung cancer in 2024, she wondered if her two adult children were at a higher risk of developing the ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors Clinically relevant actionable mutations were identified ...

Diagnosis requires a tissue biopsy for histopathologic and immunohistochemistry evaluation. Testing for alterations using non-small cell lung cancer (NSCLC) tumor tissue requires acquisition of a ...

The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...

Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. The authors have no ...

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive ...

In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical ...

Agilus Diagnostics introduces the Idylla system in Mumbai, enabling rapid genetic mutation testing for precision oncology ...